
    
      The purpose of this study is to evaluate the anti-tumor activity (best overall response) of
      the anti-epidermal growth factor receptor (EGFR) monoclonal antibody IMC-11F8 administered in
      combination with mFOLFOX-6 chemotherapy regimen in treatment-naive, locally-advanced or
      metastatic CRC participants.
    
  